Response to treatment based on RECIST v1.1 criteria and survival outcomes were assessed in the overall population, as well as based on previous FGFRi TKI exposure, primary tumor, response rate, ...

The green light from the European Commission comes a few months after pan-FGFR inhibitor Balversa (erdafitinib) was cleared for the same indication in the US, with a different label than the drug ...